This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

It is critical that novel classes of antituberculosis drugs are developed to combat the
increasing burden of infections by multidrug-resistant strains. To identify such a novel class …

Phages that infect pathogenic bacteria present a valuable resource for treating antibiotic-
resistant infections. We isolated and developed a collection of 19 Enterococcus phages …

Tuberculosis (TB) remains a global health problem despite almost universal efforts to
provide patients with highly effective chemotherapy, in part, because many infected …

Infection with Mycobacterium tuberculosis (Mtb) leading to tuberculosis (TB) disease
continues to be a major global health challenge. Critical barriers, including but not limited to …

Mycobacterium tuberculosis (Mtb) has the extraordinary ability to persist for decades within
granulomas in the human host. These histopathological structures involved in both …

Background Tuberculosis (TB) always runs in the forefront of the global burden when it
comes to infectious diseases. Tuberculosis, which can lead to impairment of quality of life …

Tuberculosis is a deadly communicable disease caused by the bacillus Mycobacterium
tuberculosis (MTB), and pulmonary tuberculosis accounts for over 80% of the total cases …

Background Evidence on factors contributing to poor treatment outcome and healthcare
priorities in vulnerable populations affected by tuberculosis (TB) in urban areas of England …